These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15155139)

  • 1. Emerging DNA topisomerase inhibitors as anticancer drugs.
    Denny WA
    Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor polycyclic acridines. Part 12. Physical and biological properties of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: a lead compound in anticancer drug design.
    Missailidis S; Stanslas J; Modi C; Ellis MJ; Robins RA; Laughton CA; Stevens MF
    Oncol Res; 2002; 13(3):175-89. PubMed ID: 12549627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
    López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
    J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
    Meikle I; Cummings J; Macpherson JS; Smyth JF
    Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
    Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
    J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of topoisomerase I inhibitors in multiple myeloma.
    Kraut EH; Ju R; Muller M
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase inhibitors as anticancer agents: a patent update.
    Khadka DB; Cho WJ
    Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
    Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
    J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
    Constantinou AI; Husband A
    Anticancer Res; 2002; 22(5):2581-5. PubMed ID: 12529967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
    Withoff S; De Jong S; De Vries EG; Mulder NH
    Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
    Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
    Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic lanostane-type triterpenoids as inhibitors of DNA topoisomerase II.
    Wada S; Tanaka R
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2966-9. PubMed ID: 15914002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
    Pindur U; Lemster T
    Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.